OsrhAAT 40 mg/kg IV ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
231α1−アンチトリプシン欠乏症1

231. α1−アンチトリプシン欠乏症


臨床試験数 : 93 薬物数 : 77 - (DrugBank : 8) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 36
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05315921
(ClinicalTrials.gov)
March 22, 202230/3/2022Study of OsrhAAT or Placebo in Healthy VolunteersA Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Single Ascending Doses of OsrhAAT in Healthy VolunteersEmphysema Secondary to Congenital AATDDrug: OsrhAAT 1 mg/kg IV;Drug: OsrhAAT 3 mg/kg IV;Drug: OsrhAAT 10 mg/kg IV;Drug: OsrhAAT 20 mg/kg IV;Drug: OsrhAAT 40 mg/kg IV;Drug: OsrhAAT 60 mg/kg IVHealthgen Biotechnology Corp.NULLRecruiting18 Years55 YearsAll48Phase 1United States